Miami, Florida, United States, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Todos Medical,
an in-vitro diagnostics company that develops reliable early-detection
blood tests and related solutions for cancer, neurodegenerative
disorders, and coronaviruses, announced the advancement of its Tollovir™
clinical trials for hospitalized COVID-19 patients.
“We
are prepped to submit the revised IRB submission for the extension
phase of the Tollovir™ Phase 2 clinical trial in hospitalized COVID
patients. In the first cohort of 32 patients, the trial not only took
death off the table for almost all patients, but it also improved their
quality of life by reducing the time the patients spent in the hospital
by 40%,” said the CEO of Todos Medical, Gerald Commissiong.
“This
preliminary data has given us the confidence to not only expand the
indications of Tollovir™ in clinical trials, but to also expand the use
of our herbal remedy and dietary immune supplement which is packed with a
powerful 3CL protease inhibitor capable of targeting the viral
persistence of Long COVID. By no means is this blind ambition because we
have already completed a very successful market research study of over
100 respondents for Tollovid™ without placebo control. The promising
results led to an increase in our marketing efforts based upon the best
resolution of symptom data related to fatigue, brain fog, and
post-exertional malaise. We want to bring realistic solutions available
now to the masses for viral persistence.”
Tollovid™’s
successor, Tollovir™, he continued, is “the result of over 20+ years of
development and an investment of over $20 million to date”. Tollovid™
was developed as an everyday antiviral herbal remedy product to be taken
in all settings, whereas Tollovir™ is being developed for more serious
medical conditions such as in the hospital or Long COVID when cytokine
storm damages tissues. Both Tollovid™ and Tollovir™ address mechanisms
critical in post-coronavirus conditions.
The
work of Todos Medical is renowned worldwide for its groundbreaking
research in medical testing. In essence, they take medical research
concepts that lack extensive exploration and provide them the resources
to produce and test the treatments of long-term ailments. Their products
represent a carefully curated combination of “eastern medicine with
western quality control”, ensuring that their testing and treatments are
well-rounded, organic, and boutique.
Commissiong
recalls that he “decided early on in the COVID pandemic to focus on
bringing supplements with pharmaceutical quality to the market.”
Impacted by the effects of COVID-19 in his personal life, he is driven
by a desire to “give people their lives back” from the disastrous
pandemic effects of persistent illnesses and ailments in the safest way
possible, which for now means botanicals.
Todos
Medical is also working to provide two new, protein-based breast cancer
diagnostic blood tests, with the first, Videssa, to be available in 2023
as well as new immunology-based Alzheimer’s blood test LymPro
completing beta-amyloid correlation studies in 2022.
In
addition to Tollovir™ reaching its second phase of clinical trials and
elevated breast cancer diagnostics on the horizon, Todos Medical is
developing organic, novel supplements to aid those affected by long-term
ailments under the guidance of Gerald Commissiong.
Disclaimer:
The information and views set out in this press release are those of
the author(s) and do not necessarily reflect the official opinion of PR
Distribution, its staff, its associates, its partners or the media
outlet(s) that this press release may be distributed on. Responsibility
for the information and views set out in this press release lies
entirely with the author(s). If you have any questions(s) pertaining to
this matter, please contact the author(s) directly at: [email protected].
BioFlorida is the voice of Florida's life sciences industry, representing 8,600 establishments and research organizations in the BioPharma, MedTech, Digital Health and Health Systems that collectively employ nearly 107,000 Floridians. Source: TEConomy/BIO (released 2022)
Print Page
Email to a Friend
